Welcome to the fifth edition of the NEMO newsletter. So much has been happening quietly behind the scenes since the last edition. We bid farewell to O4CP, who exited the consortium last November, and also completed the Trial Master File and Investigator Site Files thus marking the final step in whipping into shape the NEMO-1 documentation. We would like to thank all the PIs, investigators and study team for the hard work involved. Can we ask to join with us in welcoming to the NEMO project UPharma as our new pharmaceutical partner.The amendment of the NEMO project Technical Annex was been submitted to the EU for consideration and comment and we hope that UPharma's position in NEMO will be official shortly.